Clinical trials: Chronic Kidney Disease (CKD)
Chronic Kidney Disease, Cardiovascular Disease
Mechanisms of Chronic Kidney Disease (CKD)-Induced Foam Cell Formation
There is currently little understanding of macrophage cholesterol homeostasis and foam cell formation across the spectrum of CKD.
- Trial name
- NCT01671605
- Where
- United States
- Volunteers
- 103 people
- Sponsor
- Vanderbilt University Medical Center
Infection, Heart Failure
Rural Home Hospital: Proof of Concept
This study examines the implications of providing hospital-level care in rural homes.
- Conditions
- Infection, Heart Failure, Chronic Obstructive Pulmonary Disease, Asthma
- Trial name
- NCT04531280
- Testing
- Home hospital care
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Brigham and Women's Hospital
Fabry Disease, Chronic Kidney Disease, Stage IV (Severe)
Severe Renal Disease Study in Fabry Patients Treated With Fabrazyme
This study was designed to determine appropriate treatment with Fabrazyme at a biweekly dose of either 1 mg/kg or 3 mg/kg in a population of patients with severe renal disease burden.
- Trial name
- NCT00837824
- Testing
- Fabrazyme (agalsidase beta)
- Where
- 9 sites in United States
- Volunteers
- 20 people
- Sponsor
- Genzyme, a Sanofi Company
End Stage Renal Disease, Chronic Kidney Diseases
Berinert (C1INH) vs Placebo for DGF/IRI
This is a Phase I/II double-blind, randomized, placebo-controlled study assessing safety and limited efficacy of intraoperative C1INH (500U/kidney) vs.
- Trial name
- NCT04696146
- Testing
- Berinert
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Cedars-Sinai Medical Center
Chronic Kidney Disease (CKD)
A Phase 3b Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis
A phase 3b study for subjects receiving Epogen to compare a dosing algorithm between Hospira Epoetin and Standard of Care Epogen.
- Trial name
- NCT02504294
- Testing
- Epoetin Hospira Arm, Standard of Care Arm, IV Iron
- Where
- 45 sites in United States, Puerto Rico
- Volunteers
- 432 people
- Sponsor
- Pfizer
Chronic Kidney Disease, Hyperparathyroidism, Secondary
Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency
This study will evaluate the efficacy of CTAP101 Capsules versus placebo in reducing intact parathyroid hormone (iPTH) by at least 30% from pretreatment baseline; safety and tolerability of CTAP101 will also be evaluated
- Conditions
- Chronic Kidney Disease, Hyperparathyroidism, Secondary, Vitamin D Deficiency
- Trial name
- NCT01704079
- Testing
- CTAP101 30 μg capsules, Sugar pill to CTAP101 30 μg capsules
- Where
- United States
- Volunteers
- 216 people
- Sponsor
- OPKO IP Holdings II, Inc.
Anemia in Chronic Kidney Disease Patients Not on Dialysis
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
A phase 3, multicenter, randomized, double-blind, parallel group study. Anemic subjects with chronic kidney disease (CKD) and not on dialysis will be randomized 1:1 to 1 of 2 dosing strategies to evaluate the proportion of…
- Trial name
- START-CKD (NCT01652872)
- Testing
- Darbepoetin alfa
- Where
- 249 sites in United States, Puerto Rico
- Volunteers
- 756 people
- Sponsor
- Amgen
Chronic Kidney Disease
Study to Compare Palindrome vs. BioFlo DuraMax Dialysis Catheters
Numerous catheter designs have been studied to increase efficacy and minimize complications of catheter hemodialysis. Major complications of catheters include thrombosis, central venous stenosis, infection, and dialysis…
- Trial name
- NCT02796300
- Testing
- Bioflo Dialysis Catheter, Palindrome Dialysis Catheter
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of California, Los Angeles
Pediatric Hypertension With or Without CKD
Efficacy, Safety and Tolerability of Multiple Doses of Valsartan in Children With Hypertension With or Without CKD
To assess efficacy, safety and tolerability of valsartan when comparing two doses of valsartan in reducing and controlling blood pressure in children with hypertension with or without CKD.
- Trial name
- NCT01617681
- Testing
- VAL489
- Where
- 27 sites in Belgium, Brazil and 7 more
- Volunteers
- 127 people
- Sponsor
- Novartis Pharmaceuticals
Anemia
A Study of Subcutaneous Mircera in Participants With Chronic Kidney Disease Not Treated With ESA or on Dialysis
This single arm study will assess the efficacy and safety of subcutaneous Mircera for correction of anemia in participants with chronic kidney disease who are not treated with erythropoiesis stimulating agent (ESA) and not on…
- Trial name
- MERCUR (NCT00559637)
- Testing
- Methoxy polyethylene glycol-epoetin beta
- Where
- 50 sites in Germany
- Volunteers
- 184 people
- Sponsor
- Hoffmann-La Roche
Diabetes Mellitus, Type 2
A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease
The researchers are doing this study to see if semaglutide can slow down the growth and worsening of chronic kidney disease in people with type 2 diabetes.
- Trial name
- FLOW (NCT03819153)
- Testing
- Semaglutide
- Where
- 413 sites in United States, Argentina and 26 more
- Volunteers
- 3,533 people
- Sponsor
- Novo Nordisk A/S
Safety Issues, Chronic Kidney Diseases
Sick-Day Protocol to Improve Outcomes in Chronic Kidney Disease
The benefits of renin angiotensin system (RAS) blockers and diuretics for blood pressure control are well-established in chronic kidney diseases (CKD) patients; however, these agents may become hazardous on "sick-days" that lead…
- Trial name
- NCT03141905
- Testing
- Sick-Day Protocol, Usual Care
- Where
- United States
- Volunteers
- 342 people
- Sponsor
- University of Maryland, Baltimore
Anaemia
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
This is a four-week Phase IIa, randomized, double-blind, placebo-controlled, parallel-group, multi-center study to evaluate the safety, efficacy and pharmacokinetics of GSK1278863 in approximately 68 subjects with anemia…
- Trial name
- NCT01587898
- Testing
- GSK1278863
- Where
- 55 sites in United States, Canada and 1 more
- Volunteers
- 72 people
- Sponsor
- GlaxoSmithKline
Chronic Renal Failure
Efficacy and Safety of Everolimus+EC-MPS After Early CNI Elimination vs EC-MPS +Tacrolimus in Renal Transplant Recipients
The primary objective of this trial is to show non-inferiority of a CNI-free regimen with respect to the renal function at Month 9 post Tx assessed by glomerular filtration rate - Nankivell method - as compared to the standard…
- Trial name
- NCT00965094
- Testing
- Everolimus, Tacrolimus (FK506), Basiliximab
- Where
- 3 sites in Israel
- Volunteers
- 36 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Kidney Disease Stages 3-5
Effects of Ergocalciferol on Erythropoetin Stimulating Agent Dose
Hypothesis: The supplementation of Ergocalciferol (Vitamin D2) to those with Vitamin D deficiency in the Chronic Kidney Disease population requiring recombinant human erythropoietin for the treatment of anemia related to kidney…
- Trial name
- EASY (NCT01263028)
- Testing
- Ergocalciferol supplementation
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Kaiser Permanente
Anemia
Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease (CKD), Not on Dialysis
The purpose of the study is to evaluate the safety and efficacy of roxadustat for treatment of anemia in patients with chronic kidney disease not on dialysis
- Trial name
- NCT02174627
- Testing
- Roxadustat
- Where
- 359 sites in United States, Argentina and 24 more
- Volunteers
- 2,781 people
- Sponsor
- AstraZeneca
Healthy Volunteers (Intended Indication: Chronic Kidney Disease)
A Study to Assess the Effect of Verinurad on the Electric Activity of the Heart
This study will be conducted to investigate the safety of verinurad in healthy volunteers in combination with allopurinol 300 mg, compared with placebo in particular its effect on electrocardiogram (ECG), with focus on the QT/QTc…
- Trial name
- NCT04256629
- Testing
- Verinurad, Allopurinol
- Where
- Germany
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Anemia; Hemodialysis Dependent Chronic Kidney Disease
Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Currently Receiving ESAs With Anemia Associated With Chronic Kidney Disease in Japan
For hemodialysis subjects currently receiving ESAs with anemia associated with chronic kidney disease, demonstrate non-inferiority of MT-6548 compared to darbepoetin alfa using Hb value and evaluate long-term safety of MT-6548.
- Trial name
- NCT03439137
- Testing
- MT-6548, Darbepoetin alfa
- Where
- 28 sites in Japan
- Volunteers
- 323 people
- Sponsor
- Tanabe Pharma Corporation
Diabetic Kidney Disease, Diabetic Nephropathy
A Study in Participants With Diabetic Kidney Disease
The purpose of this study is to determine if LY2382770 is safe and effective at protecting kidney function in participants with kidney disease due to diabetes.
- Conditions
- Diabetic Kidney Disease, Diabetic Nephropathy, Diabetic Glomerulosclerosis
- Trial name
- NCT01113801
- Testing
- LY2382770
- Where
- 78 sites in United States, Australia and 5 more
- Volunteers
- 417 people
- Sponsor
- Eli Lilly and Company
Chronic Kidney Disease stage3, Chronic Kidney Disease stage4
Phase 3 Safety and Efficacy Study of CTAP101 Extended-release Capsules in Children With Secondary Hyperparathyroidism
This is a phase 3, multi-center, randomized, double-blind, placebo-controlled study in children with stage 3-4 chronic kidney disease (CKD), secondary hyperparathyroidism (SHPT) and vitamin D insufficiency.
- Conditions
- Chronic Kidney Disease stage3, Chronic Kidney Disease stage4, Vitamin d Deficiency, Secondary Hyperparathyroidism
- Trial name
- NCT05543928
- Testing
- CTAP101
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- OPKO Health, Inc.